GSK makes nice with antifungal partner Scynexis with $22M payment to resolve trial dispute
15th October 2025 Uncategorised 0Through the agreement, Scynexis will oblige GSK’s request to wind down its phase 3 study of antifungal med Brexafemme in invasive candidiasis, which it had restarted after the FDA lifted a clinical hold earlier this year.
More: GSK makes nice with antifungal partner Scynexis with M payment to resolve trial dispute
Source: fierce